Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

The Underlying Mechanisms for Olanzapine-induced Hypertriglyceridemia.

Adachi H, Yanai H, Hirowatari Y.

J Clin Med Res. 2012 Jun;4(3):206-8. doi: 10.4021/jocmr802w. Epub 2012 May 15.

2.

Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features.

Garcia-Rizo C, Fernandez-Egea E, Oliveira C, Justicia A, Bernardo M, Kirkpatrick B.

Psychiatry Res. 2012 Jul 30;198(2):212-5. doi: 10.1016/j.psychres.2011.08.014. Epub 2012 Mar 8. Erratum in: Psychiatry Res. 2013 Dec 30;210(3):1329.

3.

Magnitude of impact of executive functioning and IQ on episodic memory in Schizophrenia.

Kopald BE, Mirra KM, Egan MF, Weinberger DR, Goldberg TE.

Biol Psychiatry. 2012 Mar 15;71(6):545-51. doi: 10.1016/j.biopsych.2011.11.021. Epub 2012 Jan 23.

PMID:
22265665
4.

Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis.

Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M.

Schizophr Bull. 2013 Mar;39(2):306-18. doi: 10.1093/schbul/sbr148. Epub 2011 Dec 29. Review.

5.

Relationship between measures of inhibitory processes in patients with schizophrenia: role of substance abuse disorders.

Jurado-Barba R, Morales-Muñoz I, Del Manzano BÁ, Fernández-Guinea S, Caballero M, Martínez-Gras I, Rubio-Valladolid G.

Psychiatry Res. 2011 Dec 30;190(2-3):187-92. doi: 10.1016/j.psychres.2011.06.002. Epub 2011 Jun 24.

PMID:
21704386
6.

Alcohol use disorders contribute to hippocampal and subcortical shape differences in schizophrenia.

Smith MJ, Wang L, Cronenwett W, Goldman MB, Mamah D, Barch DM, Csernansky JG.

Schizophr Res. 2011 Sep;131(1-3):174-83. doi: 10.1016/j.schres.2011.05.014. Epub 2011 Jun 12.

7.

Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.

D'Souza MS, Markou A.

Neuropharmacology. 2012 Mar;62(3):1564-73. doi: 10.1016/j.neuropharm.2011.01.044. Epub 2011 Feb 1. Review.

8.

Linkage of cognitive impairments with metabolic disorders in schizophrenia.

Nasrallah HA.

Am J Psychiatry. 2010 Oct;167(10):1155-7. doi: 10.1176/appi.ajp.2010.10060838. No abstract available.

PMID:
20889659
9.

Metabolic syndrome with the atypical antipsychotics.

Pramyothin P, Khaodhiar L.

Curr Opin Endocrinol Diabetes Obes. 2010 Oct;17(5):460-6. doi: 10.1097/MED.0b013e32833de61c. Review.

PMID:
20717020
10.

The effects of hypertension and body mass index on cognition in schizophrenia.

Friedman JI, Wallenstein S, Moshier E, Parrella M, White L, Bowler S, Gottlieb S, Harvey PD, McGinn TG, Flanagan L, Davis KL.

Am J Psychiatry. 2010 Oct;167(10):1232-9. doi: 10.1176/appi.ajp.2010.09091328. Epub 2010 Jul 15.

PMID:
20634363
11.

Cognitive impairment in dual diagnosis inpatients with schizophrenia and alcohol use disorder.

Manning V, Betteridge S, Wanigaratne S, Best D, Strang J, Gossop M.

Schizophr Res. 2009 Oct;114(1-3):98-104. doi: 10.1016/j.schres.2009.05.020. Epub 2009 Jun 21.

PMID:
19540724
12.

Metabolic syndrome and cognitive impairment amongst elderly people in Chinese population: a cross-sectional study.

Liu CY, Zhou HD, Xu ZQ, Zhang WW, Li XY, Zhao J.

Eur J Neurol. 2009 Sep;16(9):1022-7. doi: 10.1111/j.1468-1331.2009.02640.x. Epub 2009 Apr 16.

PMID:
19473351
13.

Prevalence of alcohol use disorders in schizophrenia--a systematic review and meta-analysis.

Koskinen J, Löhönen J, Koponen H, Isohanni M, Miettunen J.

Acta Psychiatr Scand. 2009 Aug;120(2):85-96. doi: 10.1111/j.1600-0447.2009.01385.x. Epub 2009 Apr 3. Review.

PMID:
19374633
14.

Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity: A systematic comparison of their impact on cognition.

van den Berg E, Kloppenborg RP, Kessels RP, Kappelle LJ, Biessels GJ.

Biochim Biophys Acta. 2009 May;1792(5):470-81. doi: 10.1016/j.bbadis.2008.09.004. Epub 2008 Sep 23. Review.

15.

Serum leptin level and cognition in the elderly: Findings from the Health ABC Study.

Holden KF, Lindquist K, Tylavsky FA, Rosano C, Harris TB, Yaffe K; Health ABC study.

Neurobiol Aging. 2009 Sep;30(9):1483-9. doi: 10.1016/j.neurobiolaging.2007.11.024. Epub 2008 Mar 20.

16.

Hypertension and the risk of mild cognitive impairment.

Reitz C, Tang MX, Manly J, Mayeux R, Luchsinger JA.

Arch Neurol. 2007 Dec;64(12):1734-40.

17.

Contribution of metabolic syndrome components to cognition in older individuals.

Dik MG, Jonker C, Comijs HC, Deeg DJ, Kok A, Yaffe K, Penninx BW.

Diabetes Care. 2007 Oct;30(10):2655-60. Epub 2007 Jun 11.

PMID:
17563341
18.

Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking.

Ochoa EL, Lasalde-Dominicci J.

Cell Mol Neurobiol. 2007 Aug;27(5):609-39. Review.

19.

Leptin facilitates learning and memory performance and enhances hippocampal CA1 long-term potentiation and CaMK II phosphorylation in rats.

Oomura Y, Hori N, Shiraishi T, Fukunaga K, Takeda H, Tsuji M, Matsumiya T, Ishibashi M, Aou S, Li XL, Kohno D, Uramura K, Sougawa H, Yada T, Wayner MJ, Sasaki K.

Peptides. 2006 Nov;27(11):2738-49. Epub 2006 Aug 17.

PMID:
16914228
20.

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.

Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R.

Arch Gen Psychiatry. 2006 Jun;63(6):630-8.

PMID:
16754836

Supplemental Content

Support Center